
Penfluridol
CAS No. 26864-56-2
Penfluridol( R-16341 )
Catalog No. M13821 CAS No. 26864-56-2
Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
25MG | 42 | In Stock |
![]() ![]() |
50MG | 54 | In Stock |
![]() ![]() |
100MG | 68 | In Stock |
![]() ![]() |
200MG | 107 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePenfluridol
-
NoteResearch use only, not for human use.
-
Brief DescriptionPenfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.
-
DescriptionPenfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.
-
In VitroCell Viability Assay Cell Line:Human AML cell lines, HL-60 (FLT3-WT), U937 (FLT3-WT), and MV4–11 (FLT3-ITD) Concentration:1.25, 2.5, 5, 10, 20, 40 μM Incubation Time:24, 48 h Result:Significantly reduced cell viability in a concentration-dependent manner.Apoptosis AnalysisCell Line:HL-60 and U937 cells harboring FLT3-WT Concentration:7.5?μM.Incubation Time:24?h Result:Induced concentration-dependent increases in the sub-G1 population. Triggered caspase-3 activation and corresponding PARP-1 cleavage in concentration- and time-dependent manners.Cell Autophagy Assay Cell Line:U937 and HL-60 cells Concentration:1.25, 2.5, 5, 7.5 μM Incubation Time:24?h Result:5 μM and 7.5?μM respectively induced dominant LC3B-II formation and caspase-3 activation in U937 and HL-60 cells.Western Blot Analysis Cell Line:BMDMs Concentration:1 μM Incubation Time:Pretream for 2 h Result:Obviously inhibited the increased phosphorylation levels of ERK, JNK, and p38 by TNFα (10 ng/mL; 15, 30, 60 min). RT-PCR Cell Line:BMDMs Concentration:1 μM Incubation Time:Pretream for 2 h Result:Inhibited TNFα-induced mRNA expressions of IL-1β, IL-6, IL-17, and NOS2.
-
In VivoAnimal Model:DBA/1J male mice aged 10–12 weeks with type II chicken collagen-induced arthritis (CIA) model Dosage:10 mg/kg Administration:Daily oral gavage; from the 18th day after the first immunization Result: Inhibited inflammatory cell infiltration, suppressed pannus formation, and protected articular cartilage from damage. obviously decreased mRNA expressions of CXCL10 and MCP-1 in inflamed joints and statistically reduced production levels of inflammatory cytokines IL-1β and IL-6 in sera.
-
SynonymsR-16341
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number26864-56-2
-
Formula Weight523.97
-
Molecular FormulaC28H27ClF5NO
-
Purity>98% (HPLC)
-
SolubilityEthanol: 100 mg/mL (190.85 mM); DMSO: 100 mg/mL (190.85 mM)
-
SMILESOC1(C2=CC=C(Cl)C(C(F)(F)F)=C2)CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC1
-
Chemical Name1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Creese I, et al. Science, 1976 , 192(4238), 481-483.
molnova catalog



related products
-
Rotigotine
A non-selective agonist of the dopamine D3 receptor (Ki=0.71 nM); has 10-fold selectivity for the D3 receptor over the D2, D4, and D5 receptors and 100-fold selectivity for the D3 receptor over the D1 receptor.
-
NEO 376
NEO 376 is a selective 5-HT1 receptor, GABA receptor and dopamine receptor modulator, showing anti-psychotic actively.
-
Lensiprazine
Lensiprazine (SLV314) is a potent dopamine D(2) receptor antagonist that acts as a serotonin reuptake inhibitor , and can be used to study bipolar disorder and schizophrenia.